Infirst Healthcare obtains exclusive marketing rights to pair of digestive brands

WESTPORT, Conn. — The digestive brands Mylanta and Mylicon will be sold by Infirst Healthcare, following a fixed-term license agreement with McNeil Consumer Pharmaceuticals for the exclusive rights to market the products in the United States

 

“Digestive health is a high growth area and we are very excited to work with McNeil to grow these two iconic brands, which command strong consumer loyalty, professional endorsement, and trust," stated Manfred Scheske, CEO Infirst Healthcare. 

 

Infirst will market Mylanta and Mylicon through its U.S. subsidiary and working with its sales partner Advantage Consumer Healthcare, based in Pittsburgh.